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Summary
Background—Endovascular treatment (angioplasty with or without stenting) is an alternative to
carotid endarterectomy for carotid artery stenosis but there are scarce long-term efficacy data showing
that it prevents stroke. We therefore report the long-term results of the Carotid and Vertebral Artery
Transluminal Angioplasty Study (CAVATAS).
Methods—Between March, 1992, and July, 1997, patients who presented at a participating centre
with a confirmed stenosis of the internal carotid artery that was deemed equally suitable for either
carotid endarterectomy or endovascular treatment were randomly assigned to either treatment in
equal proportions by telephone or fax from the randomisation service at the Oxford Clinical Trials
Unit, UK. Patients were seen by an independent neurologist at 1 and 6 months after treatment and
then every year after randomisation for as long as possible, up to a maximum of 11 years. Major
outcome events were transient ischaemic attack, non-disabling, disabling, and fatal stroke,
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myocardial infarction, and death from any other cause. Outcomes were adjudicated on by
investigators who were masked to treatment. Analysis was by intention to treat. This study is
registered, number ISRCTN 01425573.
Findings—504 patients with stenosis of the carotid artery (90% symptomatic) were randomly
assigned to endovascular treatment (n=251) or surgery (n=253). Within 30 days of treatment, there
were more minor strokes that lasted less than 7 days in the endovascular group (8 vs 1) but the number
of other strokes in any territory or death was the same (25 vs 25). There were more cranial nerve
palsies (22 vs 0) in the endarterectomy group than in the endovascular group. Median length of follow
up in both groups was 5 years (IQR 2–6). By comparing endovascular treatment with endarterectomy
after the 30-day post-treatment period, the 8-year incidence and hazard ratio (HR) at the end of follow-
up for ipsilateral non-perioperative stroke was 11·3% versus 8·6% (HR 1·22, 95% CI 0·59–2·54); for
ipsilateral non-perioperative stroke or TIA was 19·3% versus 17·2% (1·29, 0·78–2·14); and for any
non-perioperative stroke was 21·1% versus 15·4% (1·66, 0·99–2·80).
Interpretation—More patients had stroke during follow-up in the endovascular group than in the
surgical group, but the rate of ipsilateral non-perioperative stroke was low in both groups and none
of the differences in the stroke outcome measures was significant. However, the study was
underpowered and the confidence intervals were wide. More long-term data are needed from the on
going stenting versus endarterectomy trials.
Funding—British Heart Foundation; UK National Health Service Management Executive; UK
Stroke Association.
Introduction
Carotid endarterectomy became the mainstay of treatment for patients with symptomatic
carotid artery stenosis after two randomised trials established the benefit of endarterectomy
compared with medical treatment. In recent years, endovascular treatments (first balloon
angioplasty and then stenting) have been increasingly used as an alternative to endarterectomy,
despite the paucity of evidence that endovascular treatment offers the same level of early safety
and long-term effectiveness as surgery does. Several randomised trials have compared
endovascular treatment with endarterectomy for carotid stenosis, but none have been of
sufficient duration to report outcome after longer than 4 years.
The Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS) is a
randomised controlled trial to assess the safety and efficacy of endovascular treatment
compared with endarterectomy for carotid stenosis. CAVATAS comprises three international
multicentre randomised controlled trials, which started randomisation in 1992. CAVATAS-
MED compared endovascular with medical treatment of carotid stenosis in patients who were
not suitable for surgery; only a small number of patients were randomly assigned in this
trial. CAVATAS-VER compared endovascular with medical treatment for symptomatic
vertebral artery stenosis, and the long-term results were published in 2007. CAVATAS
compared endovascular treatment (angioplasty with or without stenting) with surgery in
patients with mainly symptomatic carotid artery stenosis, and the long-term results are reported
here. We published the first report from CAVATAS—the safety outcome after 30 days of
treatment with a maximum follow-up of 3 years—in 2001. Since then, two other multicentre
randomised controlled trials that have compared carotid stenting with endarterectomy in
patients with symptomatic carotid artery stenosis have published safety data and medium-term
follow-up data, namely the Stent Protected Angioplasty versus Carotid Endarterectomy trial
(SPACE), which had a follow-up period of 2 years, and the Endarterectomy versus Angioplasty
in patients with Symptomatic Severe Carotid Stenosis trial (EVA-3S), which had a follow-up
of 4 years. However, the long-term efficacy of endovascular treatment compared with surgery
after the first few years has not been published. We therefore report the final results of
CAVATAS, including long-term data up to a maximum of 11 years' follow-up with the aim
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of assessing the long-term effectiveness of angioplasty and stenting compared with surgery in
patients with symptomatic carotid artery stenosis.
Methods
Patients
The inclusion criteria for CAVATAS have been described previously. In brief, between March,
1992, and July, 1997, patients that were referred to the 22 trial centres in western Europe,
Australia, or Canada with stenosis of the internal carotid artery that was deemed by the
investigators to require treatment and was equally suitable for carotid endarterectomy or
endovascular treatment were included in CAVATAS. Exclusion criteria included
unwillingness to undergo one of the procedures, inability to give informed consent, and
disabling stroke within the region supplied by the treated artery without useful recovery of
function. There was no upper age limit for participation in the study. All patients provided
written informed consent and each centre obtained local ethics committee approval.
Randomisation and masking
Patients were randomly assigned in equal proportions to endovascular treatment or
endarterectomy in response to a telephone call or fax to the randomisation service at the Oxford
Clinical Trials Unit, UK. Follow-up examinations were done by investigators who were
neurologically trained but were not directly involved in the endovascular treatment or
endarterectomy. All strokes and deaths were adjudicated masked to treatment allocation and
based on the information provided by the individual centres, including brain scans and, where
appropriate, death certificates.
Procedures
Participating centres used their own protocol to establish the presence of carotid stenosis, but
in most cases ultrasound findings were confirmed by catheter angiography.
All patients enrolled before 1994 who received endovascular treatment had percutaneous
balloon angioplasty. Stents suitable for the carotid artery became available during the course
of the study. From 1994, stenting was allowed at the discretion of the intervening radiologist.
Patients were seen for follow-up at 1 and 6 months after treatment, and then every year after
randomisation by an independent neurologist or stroke physician. There was no pre-determined
total length of follow-up, but investigators were encouraged to continue follow-up for as long
as they and their patients were willing to do so.
Outcome events reported to the central office were transient ischaemic attack (TIA), non-
disabling, disabling, and fatal stroke, myocardial infarction, and death from any other cause.
Amaurosis fugax was included in the category of TIA. Mortality and certified cause of death
was confirmed from the General Register Office (GRO) in patients randomly assigned at UK
centres. Stroke was defined as a clinical syndrome of acute onset of a focal neurological deficit
that lasted longer than 24 h, was of vascular origin, and was classified as disabling if the patient
required help from another person for more than 30 days as a result of the stroke. Stroke was
classified as fatal if death was deemed to be a direct result of the stroke at any time after onset.
Other stroke events were classified as non-disabling; non-disabling strokes were divided into
those that lasted fewer than 7 days and those that lasted more than 7 days, to enable comparison
with the European Carotid Surgery Trial (ECST), which only reported strokes that lasted more
than 7 days. TIA was defined as an acute disturbance of focal neurological function with
symptoms that lasted less than 24 h and was attributable to cerebrovascular disease. Death was
classified as other vascular death if it was due to any cardiovascular-related illness other than
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stroke (including myocardial infarction and pulmonary embolism). Death caused by any other
non-vascular-related illness was classified as non-vascular. If no information on the cause of
death was available, the cause was classified as undetermined. Outcome events were classified
as perioperative if they occurred at the time of treatment or within 30 days after treatment. In
patients who did not have an intervention, the date of crossover to medical treatment was
defined as the proxy-treatment date for the purpose of analysing the rate of events that occurred
more than 30 days after treatment, which were defined as non-perioperative events.
The original study protocol defined the primary outcome measure as long-term period free
from disabling stroke or death from the time of randomisation as an outcome that was relevant
to the patient and health economics. In this paper, to assess the long-term efficacy of treatment
to prevent stroke after treatment we compared the occurrence of non-perioperative TIA, stroke,
or both, in various territories, excluding perioperative events that occurred within 30 days after
treatment. Additionally, we assessed whether the use of stenting versus only balloon
angioplasty and whether the baseline characteristics, including age dichotomised at the median
age, influenced the rates of strokes that lasted more than 7 days or perioperative death. For
each outcome measure, patients were counted only once; the first event was the event of
interest, whenever this occurred. However, patients who had more than one outcome event
were counted in each relevant outcome category.
Statistical analysis
All data were analysed by intention-to-treat with SPSS version 16.0 for Mac (Chicago, IL,
USA) except where stated. The log-rank test was used to compare the survival experience free
of events in the two treatment groups. A Cox proportional hazard model was used to obtain an
estimate of the treatment effect (hazard ratio), with endarterectomy used as the reference group.
The proportional hazards assumption was checked with a graphical log-minus-log method.
Censoring was assumed to be non-informative. All outcome events up to the last available
follow-up or death of the patient were included in the calculation of hazard ratios. However,
because fewer than 50 patients were followed up beyond 8 years, Kaplan–Meier curves were
only plotted up to 8 years after randomisation. Cox regression was used to test for treatment
effect interaction within the subgroups. This study is registered, number ISRCTN 01425573.
Role of the funding source
The sponsors had no role in the study design, data collection, data analysis, data interpretation,
or the writing of the report. All authors had full access to the data in the study and had final
responsibility for the decision to submit for publication.
Results
505 patients with carotid artery stenosis who were suitable for either endovascular treatment
or carotid endarterectomy were randomly assigned to endovascular treatment (n=252), or
endarterectomy (n=253). Figure 1 shows the trial profile. One patient with carotid occlusion
was randomly assigned to endovascular treatment in error and was excluded, leaving 504
patients for the analysis. 18 patients did not receive the treatment they were allocated to. The
baseline characteristics were well balanced, and 90% of patients had symptoms within 6 months
before randomisation (table 1).
Follow-up data were available for up to 11 years after randomisation. The median length of
follow-up in both groups was 5 years (IQR 2–6 years). The use of antithrombotic medications,
control of blood pressure, and smoking rates were well matched in the two arms throughout
the course of the trial (table 1). Data on the use of statins were not collected.
Ederle et al. Page 4
Published as: Lancet Neurol. 2009 October ; 8(10): 898–907.
Sponsored D
ocum
ent 
 Sponsored D
ocum
ent 
 Sponsored D
ocum
ent
Tables 2 and 3 report the number of main outcome events. The rates of any stroke that lasted
for more than 7 days or death within 30 days of treatment were well matched between the
treatment groups (10% in each arm). There were more minor strokes that lasted fewer than 7
days within 30 days of treatment in the endovascular group than in the endarterectomy group
(8 vs 1), but there were more cranial nerve palsies in the endarterectomy group than in the
endovascular group (0 vs 22). Most cranial nerve palsies were transient, but the symptoms were
still present in one patient 1 month after treatment and had resolved by the 6-month follow-up.
The primary outcome measure of disabling stroke or death at any time after randomisation was
recorded in 238 patients (endovascular n=117, surgery n=121; table 3). The 8-year cumulative
incidence of disabling stroke or death estimated from the Kaplan–Meier survival analysis was
45·2% (SE 4·0%) in the endovascular treatment group and 50·4% (4·1%) in the endarterectomy
group (figure 2). After 8 years (data not shown) the lines for each treatment came together and
crossed, indicating an overall risk that was virtually identical in both groups (HR 1·02, 95%
CI 0·79–1·32; table 4).
Any stroke or perioperative death were more frequent in the endovascular treatment group than
they were in the surgery group. The estimated cumulative 8-year risk was 29·7% (SE 3·4%)
after endovascular treatment and 23·5% (3·5%) after surgery (figure 2). The hazard ratio
between the two treatments was not significantly different (HR 1·35, 0·94–1·93; table 4).
All the stroke outcome events recorded during follow-up longer than 30 days after treatment
lasted more than 7 days. Only one of these events (a non-disabling stroke during endovascular
treatment of restenosis in the endovascular arm) occurred as a result of carotid
revascularisation. The estimated 8-year cumulative incidence of stroke that lasted for more
than 7 days or death after randomisation, including perioperative events, was 54·4% (SE 4·0%)
in the endarterectomy group and 52·9% (4·0%) in the endovascular treatment group. The
overall risk difference was not significant (HR 1·08, 95% CI 0·85–1·38). Non-cerebrovascular
death accounted for most of the deaths. By restricting the analysis to death due to perioperative
events, there was no significant difference in the estimated 8-year occurrence of stroke that
lasted more than 7 days or perioperative death in the endovascular group (26·6%, SE 3·4%)
compared with the surgery group (23·1%, 3·5%; HR 1·19, 95% CI 0·82–1·72, figure 2 and
table 4). The estimated 8-year cumulative occurrence of any cause of death was greater after
carotid endarterectomy than it was after endovascular treatment (figure 2), but the lines for
each treatment came together and crossed after 8 years (data not shown) and the overall risk
was not significantly different (1·07, 0·82–1·40; table 4).
The combined outcome of non-perioperative stroke or TIA was more common in the
endovascular group than it was in the endarterectomy group, but the difference was not
significant (HR 1·37, 95% CI 0·95–1·97). The 8-year cumulative incidence was estimated as
36·9% (SE 5·0%) in the endovascular group and 30·2% (4·7%) in the endarterectomy group
(figure 2). Non-perioperative stroke in any territory was also more common in the endovascular
group than in the endarterectomy group, with the 8-year cumulative incidence in the
endovascular group estimated as 21·1% (SE 4·1%) compared with 15·4% (4·3%) in the
endarterectomy group; however, the difference was not significant (1·66, 0·99–2·80; figure 2
and table 4). When the analysis was restricted to ipsilateral events that occurred in the territory
of the randomised vessel, the 8-year cumulative incidence of non-perioperative stroke or TIA
was similar in the endovascular and surgery groups (19·3% [SE 4·0%] vs 17·2% [3·8%]; figure
2); the difference was not significant (1·29, 0·78–2·14; table 4). The difference was similar
when the analysis was done by treatment received rather than by intention-to-treat (1·25, 0·76–
2·06).
The estimated cumulative 8-year incidence of non-perioperative ipsilateral stroke was 11·3%
(SE 3·7%) in the endovascular group and 8·6% (3·1%) in the endarterectomy group (figure 2).
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The overall risk difference was not significant when the data were analysed by intention-to-
treat (1·22, 0·59–2·54; table 4) or by treatment received (1·10, 0·53–2·28). The cumulative
incidence of non-perioperative stroke in a non-randomised vascular territory (contralateral or
vertebrobasilar) at 8 years was also not significantly different (11·6% [SE 2·5%] vs 11·2%
[4·2%]; 1·90, 0·97–3·73).
23% (n=55) of the patients randomly assigned to endovascular treatment had stenting. The
remaining patients were treated with balloon angioplasty only. The 8-year cumulative
occurrence of stroke that lasted for more than 7 days or perioperative death, analysed by
treatment received, was 24% after balloon angioplasty, 34% after stenting, and 21% after
endarterectomy. The higher risk in patients who had stenting compared with those treated by
balloon angioplasty only was not significant (1·33, 0·72–2·46). This outcome included patients
whose stroke occurred at the time of balloon insertion but before the stent was deployed.
Excluding perioperative events, the risk of ipsilateral non-perioperative stroke was lower after
stenting than it was after angioplasty alone, but the difference was not significant (0·66, 0·25–
1·71).
Subgroup analysis to assess the influence of baseline variables on the long-term rate of any
stroke that lasted more than 7 days or perioperative death showed no significant interaction
with treatment effect of any of the variables tested (figure 3). In patients younger than 68 years,
there was no significant difference in the rate of stroke or perioperative death between
endovascular treatment and endarterectomy (1·05, 0·61–1·83). Although the HR was higher in
patients aged 68 years or older (1·32, 0·79 to 2·20), this was not significant. Furthermore, the
HR for endovascular treatment compared with endarterectomy was non-significantly greater
in patients with ischaemic heart disease (1·88, 1·00–3·54).
Discussion
CAVATAS was a randomised controlled trial of endovascular treatment compared with
endarterectomy for the treatment of mainly symptomatic carotid artery stenosis. CAVATAS
was designed to provide data on two main questions regarding the endovascular treatment of
atherosclerotic carotid artery stenosis. First, how safe is endovascular treatment compared with
carotid endarterectomy in terms of 30-day outcome events; second, how do the two procedures
compare in terms of their long-term effectiveness in preventing post-treatment stroke. The
initial short-term data, published in 2001, showed similar rates of the major complications of
stroke lasting more than 7 days or death, within 30 days of treatment, but the rates in both arms
were unacceptably high (around 10%), which mandated further trials to compare stenting with
endarterectomy for symptomatic carotid stenosis and determine whether the safety of treatment
could be improved. Several of these have published their initial findings of outcome events
within 30 days of the procedure. The most recent of these, EVA-3S and SPACE, did not
establish the equivalence of carotid stenting with endarterectomy in terms of early safety. We
concluded in our recent meta-analysis of all available randomised data that the results of the
trials did not support a change in clinical practice away from recommending carotid
endarterectomy as the treatment of choice for suitable carotid artery stenosis. Moreover, the
long-term efficacy of endovascular treatment to prevent stroke, which is the main aim of the
treatment of carotid stenosis, remained unclear.
Here, we have reported new data on the safety of the endovascular treatment. In the original
analysis published in 2001, the steering committee prospectively decided that only strokes that
lasted longer than 7 days would be included in the analysis of perioperative events occurring
within 30 days of treatment, to match the European Carotid Surgery Trial (ECST), which also
only reported strokes that lasted longer than 7 days. This criterion was also chosen to avoid
ascertainment bias related to the concern that some short-lived events would be missed in
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patients who had surgery and were operated on under general anaesthesia and returned to
surgical wards compared with patients who had endovascular treatment under local anaesthesia
and were returned immediately to neurological wards. Our current finding that minor strokes
with symptoms that lasted fewer than 7 days were reported more frequently in the 30 days after
treatment in the endovascular arm than in the endarterectomy arm (8 vs 1), whereas there was
no significant difference in the rate of stroke that lasted longer than 7 days, or death, could be
seen as confirmation of an ascertainment bias in favour of the minor strokes, or could show
additional hazards from endovascular treatment at the time. The number of minor strokes in
the endovascular group was more than offset by the number of cranial nerve palsies after
endarterectomy (8 minor strokes vs 22 cranial nerve palsies), one of which did not resolve until
the 6 month follow-up.
The final results of CAVATAS reported here provide the first randomised data on the long-
term outcome up to 11 years after endovascular treatment. Most events during follow-up (62%)
were deaths, and the 5-year and 10-year risks of mortality were 22% and 75%, respectively.
The long-term rate of ipsilateral stroke was similar to that recorded in the endarterectomy arms
of previous trials: ECST reported a 10-year risk of ipsilateral stroke after carotid
endarterectomy (excluding perioperative events) of 9·7%, which is similar to the 8-year risk
of 8·6% after surgery and 11·3% after endovascular treatment reported here. The comparison
of the primary outcome measure of long-term survival free of disabling stroke or death
(including perioperative events) in CAVATAS showed no difference between endovascular
treatment and endarterectomy (HR 1·02, 95% CI 0·79–1·32) and the rate after randomisation
of any stroke that lasted longer than 7 days or perioperative death was also not significantly
different (1·19, 0·82–1·72). There was also no significant difference in the rate of outcome
events between the two arms if only events occurring more than 30 days after treatment are
analysed, although there were more events in those patients allocated to endovascular
treatment. EVA-3S and SPACE also found little difference in the rates of ipsilateral non-
perioperative stroke more than 30 days after treatment when patients assigned to carotid
stenting were compared with those assigned to endarterectomy over a shorter length of follow-
up (maximums of 4 and 2 years, respectively). The result of a meta-analysis of the data from
all three trials suggested that both methods of treatment have similar efficacy at preventing
long-term ipsilateral stroke after the treatment period (figure 4), but with wide confidence
intervals (odds ratio 1·18, 95% CI 0·70–1·99). Further long-term data are needed from the large
on going randomised stenting trials, to ascertain whether the small difference in favour of
endarterectomy becomes significant or not with larger numbers of patients and outcome events.
CAVATAS was one of the earliest clinical trials of endovascular treatment, and most patients
in the endovascular treatment group were treated with just angioplasty. Stenting was primarily
used as a secondary procedure when balloon angioplasty alone produced an unsatisfactory
result. Stents were used in 55 patients (26%), in whom endovascular treatment was deemed
technically successful (balloon inflation or stent deployment across the lesion). Primary
stenting has subsequently replaced balloon angioplasty as the radiological technique of choice
for carotid stenosis. Additionally, the technical equipment used in endovascular treatment has
improved since CAVATAS. However, there are no data from randomised trials to support the
notion that stenting is superior to angioplasty alone. The exploratory subgroup analysis of
patients treated with stenting compared with those treated with only balloon angioplasty
showed no significant difference in the risk of stroke that lasted more than 7 days or
perioperative death (1·33, 0·72–2·46), but this outcome included some patients whose stroke
occurred as a result of full balloon deployment before a stent was inserted as a rescue procedure.
The risk of ipsilateral non-perioperative stroke was lower after stenting than after angioplasty
alone, but the number of events was small and the difference was not significant (0·66, 0·25–
1·71).
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One of the concerns about endovascular techniques is that angioplasty and stenting might be
associated with a higher rate of restenosis than is endarterectomy. We report the results of
analysis of the ultrasound follow-up from those centres in CAVATAS where ultrasound was
available in a companion paper. The ultrasound data confirmed that severe restenosis (≥70%)
was found significantly more commonly in patients after endovascular treatment than after
endarterectomy, and the long-term risk of severe carotid restenosis or occlusion in CAVATAS
was three times higher after endovascular treatment than after endarterectomy (adjusted HR
3·17, 1·89–5·32; p<0·0001). Severe carotid restenosis or occlusion after endovascular treatment
or endarterectomy was also associated with an increased risk of recurrent ipsilateral
cerebrovascular events (adjusted HR for the rate of ipsilateral non-perioperative stroke or TIA
2·18, 1·04–4·54; p=0·04) but the increase in recurrent ipsilateral stroke alone was not significant
(1·67, 0·54–5·11; p=0·4).
Several tests were done to ascertain whether risk factors predicted outcome, regardless of
treatment allocation. None of these subgroup analyses showed a significant interaction between
baseline variables and treatment effect. In patients younger than 68 years there was no
difference in risk of stroke that lasted more than 7 days or perioperative death according to
treatment allocation (1·05, 0·61–1·83), but the hazard ratio for endovascular treatment in
patients aged 68 years or older was higher than that for endarterectomy (1·32, 0·79–2·20).
Although little emphasis can be placed on this finding, these results are consistent with the
findings reported by the EVA-3S and SPACE investigators. The subgroup analyses also
suggest that patients with ischaemic heart disease might have a lower long-term rate of stroke
after treatment with endarterectomy than after treatment with endovascular methods.
In conclusion, more patients in the endovascular group had a stroke during follow-up than did
patients in the surgical group, but the rate of ipsilateral non-perioperative stroke was low in
both groups and none of the differences in the stroke outcome measures reached statistical
difference. However, the study was underpowered and the confidence intervals are wide. The
low rate of long-term stroke longer than 30 days after endovascular treatment supports the use
of endovascular treatment to prevent long-term stroke in patients in whom carotid
endarterectomy is contraindicated or who prefer to risk the possibly greater hazard of
endovascular treatment over surgery. However, the results do not support the use of
endovascular treatment in preference to surgery in patients who are suitable for both treatments;
there were also more minor strokes within 30 days of endovascular treatment and a greater
incidence of restenosis. These results emphasise the need for further data from the short-term
and long-term comparison of endovascular treatment with endarterectomy in trials that are on
going, including the International Carotid Stenting Study (ICSS) and the Carotid
Revascularisation Endarterectomy versus Stent Trial (CREST). There is a strong suggestion
from the subgroup analysis of SPACE and EVA-3S, which is supported by the subgroup
analysis in CAVATAS, that the small additional hazard of endovascular treatment applies only
to older patients and that the two treatments might be equivalent in young patients. The Carotid
Stenting Trialists Collaboration has recently been established to analyse the pooled data from
the recent large trials, to establish more clearly in which subgroups endarterectomy is the
treatment of choice and in which subgroups endovascular treatment has equivalent risks.
Stenting avoids some of the minor complications of carotid endarterectomy and therefore
would be the treatment of choice in any subgroups in which it could be shown to have equivalent
safety and long-term outcome.
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Figure 1.
Trial profile
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Figure 2.
Kaplan–Meier estimates of cumulative incidence
The numbers above and below the lines refer to the 8-year incidence (SE) (%). (A) Disabling
stroke or death (primary outcome measure). (B) Any stroke or perioperative death. (C) Stroke
that lasted more than 7 days or perioperative death within 30 days of treatment. (D) Non-
perioperative stroke or TIA. (E) Non-perioperative stroke. (F) Non-perioperative ipsilateral
stroke or transient ischaemic attack. (G) Non-perioperative ipsilateral stroke. (H) Any cause
of death. Except where stated, stroke refers to events in any territory. A, B, C, and H are
analysed from date of randomisation; D and G are analysed from 30 days after treatment. No
stroke that occurred more than 30 days after treatment lasted for fewer than 7 days.
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Figure 3.
Subgroup analysis to compare the rates of the outcome event of stroke in any territory that
lasted more than 7 days or perioperative death, according to various baseline characteristics
p values are associated with treatment–covariate interaction tests. The dotted vertical line is
the hazard ratio in the overall population. Analyses are by intention to treat. n=number of
events. N=number of patients in each group. EVT=endovascular treatment. CEA=carotid
endarterectomy. HR=hazard ratio. TIA=transient ischaemic attack. MI=myocardial infarction.
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Figure 4.
Meta-analysis of the main multicentre randomised controlled trials
Comparison of long-term benefit of endovascular treatment versus endarterectomy for
symptomatic carotid artery stenosis in prevention of non-perioperative ipsilateral stroke. The
summary estimate statistic is a Peto odds ratio (fixed-effect model), the centre of the diamond
is the point estimate, and the ends of the line are the 95% CI. The I-square statistic gives an
indication of heterogeneity, where 0% suggests that it might not be important. The value of I-
squared depends on the magnitude and direction of effects and the strength of evidence for
heterogeneity (p value from χ2 test).
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Table 1
Patient characteristics at baseline
Endovascular treatment (n=251) Endarterectomy (n=253)
Age (years) 68 (62–73) 68 (62–73)
Sex
Women 77 (31%) 75 (30%)
Men 174 (69%) 178 (70%)
Vascular risk factors
Hypertension 132 (53%) 144 (58%)
Systolic blood pressure (mm Hg) 151·8 (21·8) 152·6 (20·1)
Diastolic blood pressure (mm Hg) 83·5 (11·8) 83·9 (10·7)
Diabetes mellitus 35 (14%) 32 (13%)
Cholesterol >6·5 mmol/L 67 (34%) 62 (32%)
Smoker (past or current) 191 (77%) 192 (78%)
History of cardiovascular or cerebrovascular disease
Myocardial infarction 43 (19%) 40 (17%)
Atrial fibrillation 12 (5%) 12 (5%)
Peripheral vascular disease 60 (24%) 51 (20%)
Cerebrovascular symptoms >6 months before
randomisation
21 (8%) 15 (6%)
Treatments at randomisation
Antiplatelet 216 (86%) 230 (91%)
Warfarin 23 (10%) 28 (11%)
Cerebrovascular events within 6 months before randomisation
Transient ischaemic attack 94 (37%) 98 (39%)
Amaurosis fugax 60 (24%) 63 (25%)
Hemisphere stroke
Minor 19 (8%) 20 (8%)
Major (non-disabling) 32 (13%) 28 (11%)
Major (disabling) 11 (4%) 18 (7%)
Retinal infarct 5 (2%) 3 (1%)
Degree of symptomatic carotid stenosis*
60–69% 15 (6%) 16 (6%)
70–79% 34 (14%) 40 (16%)
80–89% 91 (36%) 92 (36%)
90–99% 109 (43%) 98 (39%)
Contralateral carotid stenosis of 70–99% or
occlusion*
78 (31%) 79 (32%)
Time from randomisation to treatment (days) 20·0 (8·0–32·0) 27·0 (13·5–41·0)
Follow-up (years) 5 (2–6) 5 (2–6)
Treatments, blood pressure, and smoking status during follow-up†
Antiplatelet 202 (92%) 209 (90%)
43 (86%) 47 (90%)
Warfarin 12 (6%) 12 (5%)
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Endovascular treatment (n=251) Endarterectomy (n=253)
4 (8%) 2 (4%)
Systolic blood pressure (mm Hg) 151·0 (21·0) 151·0 (23·4)
153·9 (23·2) 147·6 (26·5)
Diastolic blood pressure (mm Hg) 83·0 (10·1) 82·7 (10·2)
78·3 (12·3) 77·6 (14·0)
Smoker (past or current) 48 (23%) 50 (22%)
5 (11%) 12 (27%)
Data are number (%), median (IQR), or mean (SD) unless otherwise indicated.
*
Measured by common carotid method.
†
The first line for each characteristic is taken from 1-year follow-up data and the second line from the 6-year follow-up data.
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Table 2
Outcome events within 30 days after first treatment
Endovascular treatment (n=251) Endarterectomy (n=253)
Fatal stroke 7 (3%) 1 (0·3%)
Non-stroke death 0 3 (2%)
Disabling stroke 9 (4%) 11 (4%)
Non-disabling stroke that lasted more than 7 days 9 (4%) 10 (4%)
Non-disabling stroke that lasted fewer than 7 days 8 (3%) 1 (0.3%)
Death or disabling stroke 16 (6%) 15 (6%)
Death or any stroke that lasted more than 7 days 25 (10%) 25 (10%)
Cranial nerve palsy* 0 22 (9 %)
Haematoma that required surgery or extended stay in
hospital†
3 (1%) 17 (7%)
Non-fatal myocardial infarction 0 3 (1%)
Pulmonary embolus 0 2 (1%)
Data are number (%). Stroke refers to events in any territory.
*
p<0·0001.
†
p <0·002. Other differences not significant.
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Table 3
Major long-term outcome events
Endovascular treatment (n=251)* Endarterectomy (n=253)†
Disabling stroke or death 117 121
Stroke 33 27
Disabling 18 21
Fatal 15 6
Non-stroke death 84 94
Stroke that lasted >7 days or death 134 131
Stroke that lasted >7 days 59 47
Fatal 14 6
Disabling 17 19
Non-disabling 28 22
Non-stroke death 75 84
Perioperative 0 3
Non-perioperative 75 81
Any stroke or perioperative death 67 51
Any stroke 67 48
Fatal 14 6
Disabling 17 19
Non-disabling >7 days 28 22
Non-disabling <7 days 8 1
Perioperative death 0 3
Vascular non-stroke 0 2
Non-vascular 0 1
Non-perioperative stroke or TIA 67 51
Non-perioperative stroke 31 18
Fatal 6 4
Disabling 7 5
Non-disabling 18 9
Non-perioperative TIA 36‡ 33§
Non-perioperative ipsilateral stroke or TIA 34 27
Non-perioperative ipsilateral stroke 12 11
Fatal 1 1
Disabling 3 2
Non-disabling 8 8
Non-perioperative ipsilateral TIA 22¶ 16‖
Non-perioperative non-ipsilateral stroke 24 13
Fatal 8 4
Disabling 5 6
Non-disabling 11 3
Death 112 113
Stroke death 16 6
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Endovascular treatment (n=251)* Endarterectomy (n=253)†
Vascular non-stroke death 43 53
Non-vascular 44 46
Undetermined 9 8
Data are number of events. None of the differences were statistically significant. Indented lines below combined outcome measures indicate how many
events contributed to the combined outcome measure. All non-perioperative strokes lasted for more than 7 days. TIA=transient ischaemic attack.
*
Total person-years of follow-up=1098.
†
Total person-years of follow-up=1083.
‡
6 patients had a subsequent non-perioperative stroke (1 fatal, 2 disabling, 3 non-disabling).
§
5 patients had a subsequent non-perioperative stroke (1 fatal, 3 disabling, 1 non-disabling).
¶
4 patients had a subsequent non-perioperative ipsilateral stroke (1 disabling, 3 non-disabling).
‖
2 patients had a subsequent non-perioperative ipsilateral stroke (1 disabling, 1 non-disabling).
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Table 4
Hazard ratios for all outcome measures
Hazard ratio (95% CI)
Disabling stroke or death 1·02 (0·79–1·32)
Any stroke lasting > 7 days or death 1·08 (0·97–3·73)
Any stroke or perioperative death 1·35 (0·94–1·93)
Stroke lasting >7 days or perioperative death 1·19 (0·82–1·72)
Non-perioperative stroke or TIA 1·37 (0·95–1·97)
Non-perioperative stroke 1·66 (0·99–2·80)
Non-perioperative ipsilateral stroke or TIA 1·29 (0·78–2·14)
Non-perioperative ipsilateral stroke 1·22 (0·59–2·54)
Non-perioperative, non-ipsilateral stroke 1·08 (0·97–3·73)
Any cause of death 1·07 (0·82–1·40)
Data are hazard ratio (95% CI). Hazard ratios are calculated by intention-to-treat and are based on all available follow-up to a maximum of 11 years.
TIA=transient ischaemic attack.
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